103 related articles for article (PubMed ID: 12431031)
1. Glufosfamide (Baxter Oncology).
Niculescu-Duvaz I
Curr Opin Investig Drugs; 2002 Oct; 3(10):1527-32. PubMed ID: 12431031
[TBL] [Abstract][Full Text] [Related]
2. Glufosfamide: beta-D-Glc-IPM, D 19575.
Drugs R D; 2005; 6(1):49-52. PubMed ID: 15801867
[TBL] [Abstract][Full Text] [Related]
3. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent.
Dollner R; Dietz A; Kopun M; Helbig M; Wallner F; Granzow C
Anticancer Res; 2004; 24(5A):2947-51. PubMed ID: 15517901
[TBL] [Abstract][Full Text] [Related]
5. [Perfect drug targeting. Glufosfamide a new derivative].
Holzgrabe U
Pharm Unserer Zeit; 2006; 35(2):158-9. PubMed ID: 16583570
[No Abstract] [Full Text] [Related]
6. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent.
Seker H; Bertram B; Bürkle A; Kaina B; Pohl J; Koepsell H; Wiesser M
Br J Cancer; 2000 Feb; 82(3):629-34. PubMed ID: 10682676
[TBL] [Abstract][Full Text] [Related]
7. [Identification of glufosfamide metabolites in rats].
Sun YM; Chen XY; Zhong DF
Yao Xue Xue Bao; 2006 Jun; 41(6):513-7. PubMed ID: 16927824
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of glufosfamide in childhood acute leukemia.
Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
[TBL] [Abstract][Full Text] [Related]
9. Stability of glufosfamide in phosphate buffers and in biological samples.
Sun Y; Chen X; Xu H; Guan Z; Zhong D
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Mar; 832(2):224-30. PubMed ID: 16455312
[TBL] [Abstract][Full Text] [Related]
10. Possible contribution of beta-glucosidase and caspases in the cytotoxicity of glufosfamide in colon cancer cells.
Arafa HM
Eur J Pharmacol; 2009 Aug; 616(1-3):58-63. PubMed ID: 19545561
[TBL] [Abstract][Full Text] [Related]
11. Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
Zhang J; Tian Q; Chan SY; Duan W; Zhou S
Drug Resist Updat; 2005 Oct; 8(5):271-97. PubMed ID: 16154799
[TBL] [Abstract][Full Text] [Related]
12. BNP-7787 (BioNumerik/Baxter Oncology/Grelan).
Reilly RT
IDrugs; 2004 Jan; 7(1):64-9. PubMed ID: 14730469
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
14. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
Ciuleanu TE; Pavlovsky AV; Bodoky G; Garin AM; Langmuir VK; Kroll S; Tidmarsh GT
Eur J Cancer; 2009 Jun; 45(9):1589-96. PubMed ID: 19188061
[TBL] [Abstract][Full Text] [Related]
15. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
Giaccone G; Smit EF; de Jonge M; Dansin E; Briasoulis E; Ardizzoni A; Douillard JY; Spaeth D; Lacombe D; Baron B; Bachmann P; Fumoleau P;
Eur J Cancer; 2004 Mar; 40(5):667-72. PubMed ID: 15010066
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Opydo-Chanek M; Mazur L; Stojak M
Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
[TBL] [Abstract][Full Text] [Related]
17. Induction of DNA breakage in U937 cells by oxazaphosphorines.
Mazur L; Opydo-Chanek M; Stojak M; Baran J; Niemeyer U
Folia Biol (Krakow); 2010; 58(1-2):15-20. PubMed ID: 20420190
[TBL] [Abstract][Full Text] [Related]
18. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
19. N-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4-aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustard.
Jiang Y; Hu L
Bioorg Med Chem Lett; 2008 Jul; 18(14):4059-63. PubMed ID: 18556201
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of glyciphosphoramide used alone and in combination with other drugs].
Wang ZY
Zhonghua Zhong Liu Za Zhi; 1984 Sep; 6(5):379-81. PubMed ID: 6398774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
